celecoxib has been researched along with Cancer of Pancreas in 57 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Herein, the effects of the PGHS-2-specific inhibitor celecoxib either alone or in combination with the green tea-derived catechin (-)-epigallocatechin-3-gallate (EGCG) were studied on the expression of interleukin (IL)-1-induced tumorigenic factors in Colo357 human pancreatic adenocarcinoma cells." | 7.78 | (-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357. ( Falk, W; Härdtner, C; Multhoff, G; Radons, J, 2012) |
| "Capecitabine was administered at a dose of 1,000 mg/m(2) b." | 6.74 | Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. ( Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I, 2009) |
| "Celecoxib treatment suppressed FGF-2 and FGFR-2 expression and decreased MMP-2, MMP-9 and p-ERK expression in the PANC-1 cells." | 5.43 | Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells. ( Dong, L; Li, J; Luo, M; Shang, B; Wang, Y, 2016) |
| " Recent studies had shown that the long-term use of high concentration of COX-2 inhibitors is not toxic free and may be limited due to serious gastrointestinal and cardiovascular side effects." | 5.33 | Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. ( Arber, N; Ben-Yosef, R; Figer, A; Kazanov, D; Lev-Ari, S; Starr, A; Yona, D; Zinger, H, 2005) |
| "Single agent gemcitabine (GEM) is the standard treatment of pancreatic adenocarcinoma." | 5.12 | Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Nodari, F; Rangoni, G; Simoncini, E; Strina, C; Tiberio, GA; Valcamonico, F; Vassalli, L, 2006) |
| " Herein, the effects of the PGHS-2-specific inhibitor celecoxib either alone or in combination with the green tea-derived catechin (-)-epigallocatechin-3-gallate (EGCG) were studied on the expression of interleukin (IL)-1-induced tumorigenic factors in Colo357 human pancreatic adenocarcinoma cells." | 3.78 | (-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357. ( Falk, W; Härdtner, C; Multhoff, G; Radons, J, 2012) |
| " In this study, we show that a novel Mucin-1 (MUC1)-based vaccine in combination with a cyclooxygenase-2 inhibitor (celecoxib), and low-dose chemotherapy (gemcitabine) was effective in preventing the progression of preneoplastic intraepithelial lesions to invasive pancreatic ductal adenocarcinomas." | 3.75 | Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. ( Arefayene, M; Basu, GD; Bradley, JM; De Petris, G; Mukherjee, P; Skaar, T; Subramani, DB; Tinder, TL, 2009) |
| " Here we characterized the effects of non-selective (indomethacin) and selective (NS398, celecoxib) cyclooxygenase inhibitors on parameters of angiogenesis in human pancreatic adenocarcinoma cells." | 3.72 | Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. ( Davis, DW; Ellis, LM; Khanbolooki, S; Lashinger, LM; McConkey, DJ; Nawrocki, S; Raut, CP; Xiong, H, 2004) |
| "It has been suggested that the optimal treatment for cachexia should be a multimodal intervention." | 2.84 | A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. ( Balstad, TR; Bye, A; Fallon, M; Fayers, P; Fearon, K; Johns, N; Kaasa, S; Laird, BJA; Pettersen, CH; Solheim, TS; Stene, GB, 2017) |
| "Based on the lack of response, the substantial toxicity of mainly gastro-intestinal origin and the reported mediocre overall and progression free survival, we cannot advise our short intensive chemoradiotherapy schedule combined with celecoxib as the standard treatment." | 2.76 | Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. ( Busch, OR; Morak, MJ; Nuyttens, JJ; Padmos, EE; Richel, DJ; Schaake, EE; van der Gaast, A; van Eijck, CH; van Tienhoven, G; Vervenne, WL, 2011) |
| "Capecitabine was administered at a dose of 1,000 mg/m(2) b." | 2.74 | Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. ( Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I, 2009) |
| "The direct pancreatic cancer xenograft model proved to be a valuable tool for drug evaluation and biological studies and showed similar results to those observed in resected pancreatic cancer specimens." | 2.72 | Assessment of celecoxib pharmacodynamics in pancreatic cancer. ( Almuete, V; Amador, ML; Chan, A; Danenberg, K; Hidalgo, M; Hruban, RH; Jimeno, A; Kulesza, P; Kuramochi, H; Maitra, A; Messersmith, WA; Rubio-Viqueira, B; Tanaka, K; Wang, X; Wheelhouse, J; Yeo, CJ; Zhang, X, 2006) |
| "The median time to disease progression was 8 weeks, and the median overall survival was 15 weeks." | 2.71 | Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. ( Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Gelibter, A; Malaguti, P; Milella, M; Pellicciotta, M; Ruggeri, EM; Terzoli, E, 2004) |
| "Pancreatic cancer is amongst the most chemoresistant malignancies." | 2.71 | A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. ( Adsay, V; El-Rayes, BF; Ferris, AM; Heilbrun, LK; Philip, PA; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2005) |
| "Patients with advanced pancreatic cancer who had not received chemotherapy and had acceptable organ function were eligible for the study." | 2.71 | A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. ( Abbruzzese, JL; Du, M; Lenzi, R; Plunkett, W; Wolff, R; Xiong, HQ, 2005) |
| "Unresectable pancreatic cancer has few therapeutic options and a dismal prognosis." | 2.71 | Gemcitabine/Irinotecan/celecoxib in pancreatic cancer. ( Campbell, C; Harvey, H; Kerr, S; Legore, K; Lipton, A; Witters, L, 2004) |
| "The low survival rate of patients with pancreatic cancer points towards an increased need for novel therapeutic and chemopreventive strategies and also early detection of this disease." | 2.46 | Chemoprevention strategies for pancreatic cancer. ( Brand, RE; Singh, SV; Stan, SD, 2010) |
| " However, recent studies showed that long term use of high doses of celecoxib is associated with an increased cardiovascular toxicity." | 2.44 | Compositions for treatment of cancer and inflammation. ( Arber, N; Lev-Ari, S; Lichtenberg, D, 2008) |
| "Pancreatic cancer is a lethal disease that is resistant to chemotherapy and radiotherapy." | 2.42 | Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. ( Crane, CH; Janjan, NA; Mason, K; Milas, L, 2003) |
| "Capecitabine is an oral 5-fluorouracil (5-FU) prodrug that is more convenient than using infusional 5-FU, appears to have a similar therapeutic profile, and can be combined with daily irradiation." | 2.42 | COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas. ( Rich, TA; Shepard, R, 2003) |
| " Combined atorvastatin with celecoxib and tipifarnib synergistically decreased the sphere forming ability of Panc-1 cells and the drug combination also strongly inhibited cell proliferation and promoted apoptosis in the sphere-forming cells." | 1.62 | Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells. ( Chen, J; Goodin, S; Li, DL; Ma, YR; Ma, YY; Ren, X; Wang, X; Xu, XT; Zhang, K; Zhao, DG; Zheng, X; Zhou, RP, 2021) |
| "The progression and metastasis of pancreatic ductal adenocarcinoma (PDAC) is highly dependent on the tumour microenvironment." | 1.51 | Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. ( Bai, X; Chen, Q; Chen, Y; Dang, X; Fu, Q; Liang, T; Lou, Y; Wang, J; Wei, T; Yang, J; Ye, M; Zhang, J; Zhang, Q; Zhang, X, 2019) |
| "L1CAM was highly expressed in pancreatic cancer tissue and positively correlated with age, TNM staging and tumor differentiation." | 1.48 | Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3 / NF-kB and L1CAM activities. ( Hong, Y; Liu, N; Liu, Z; Ma, M; Qiu, X; Sheng, X; Tang, B; Xiong, S; Yang, D; Zhou, K; Zuo, C, 2018) |
| "Celecoxib treatment suppressed FGF-2 and FGFR-2 expression and decreased MMP-2, MMP-9 and p-ERK expression in the PANC-1 cells." | 1.43 | Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells. ( Dong, L; Li, J; Luo, M; Shang, B; Wang, Y, 2016) |
| "Human pancreatic cancer cell line PANC-1 cells were treated with diverse concentrations of celecoxib (20, 60, 100 μmol/L)." | 1.42 | Anti-tumor effect and mechanism of cyclooxygenase-2 inhibitor through matrix metalloproteinase 14 pathway in PANC-1 cells. ( Gu, Z; Li, J; Li, S; Sun, K; Xiao, Z; Zhou, T, 2015) |
| "The most glycolytic pancreatic cancer cell line was exquisitely sensitive to 2-DG, whereas the least glycolytic pancreatic cancer cell was resistant to 2-DG." | 1.40 | Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. ( Cheng, G; Dwinell, MB; Kalyanaraman, B; McAllister, D; Tsai, S; Zielonka, J, 2014) |
| "Pancreatic cancer is a major health problem because of its aggressiveness and the lack of effective systemic therapies." | 1.36 | Effects of capecitabine and celecoxib in experimental pancreatic cancer. ( Arjona-Sánchez, A; Cruz, A; Muñoz, Mdel C; Muntané, J; Padillo, FJ; Perea, MD; Ruiz-Rabelo, J; Túnez, I; Vázquez, R, 2010) |
| "Melatonin (MEL) has antioxidant activity and prevents experimental genotoxicity." | 1.36 | Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer. ( Cruz, A; Montilla, P; Muntané, J; Padillo, FJ; Perea, MD; Ruiz-Rabelo, JF; Tasset, I; Túnez, I, 2010) |
| "Future pancreatic cancer trials should consider lower-dose nonsteroidal anti-inflammatory drugs in combination with VEGF inhibitors." | 1.36 | Vascular endothelial growth factor and not cyclooxygenase 2 promotes endothelial cell viability in the pancreatic tumor microenvironment. ( Conlon, KC; Geary, M; Manahan, E; McKeown, C; McMillan, H; Murphy, JF; Rogers, A; Toomey, DP, 2010) |
| "The treatment of the human pancreas carcinoid cell line BON and the mouse insulinoma cell line beta-TC-3 with EGFR and COX-2 inhibitors (monotherapy and combined therapy) resulted in a significant, dose-dependent reduction of cell viability coupled with increased apoptosis." | 1.35 | Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? ( Bergmann, F; Breinig, M; Ehemann, V; Esposito, I; Fischer, L; Friess, H; Herpel, E; Höpfner, M; Kern, MA; Kleeff, J; Köhler, C; Rieker, RJ; Schirmacher, P, 2009) |
| "Tumor invasion into adjacent organs and metastasis were not observed in the DMAPT/celecoxib treatment groups." | 1.35 | Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. ( Crooks, PA; Holcomb, B; Neelakantan, S; Njoku, V; Ralstin, M; Schmidt, CM; Sweeney, CJ; Wu, H; Yip-Schneider, MT, 2008) |
| " In the present study, we determined the effects of 3,3'-diindolylmethane (Bioresponse BR-DIM referred to as B-DIM), a formulated DIM with greater bioavailability on cell viability and apoptosis with erlotinib in vitro and in vivo using an orthotopic animal tumor model." | 1.35 | Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. ( Ahmad, A; Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH, 2008) |
| "Gemcitabine was administered intraperitoneally twice a week, and celecoxib was given via water daily." | 1.33 | [Enhancing effects of celecoxib on the growth inhibition of pancreatic carcinoma by gemcitabine treatment]. ( Wang, XP; Wu, K; Xu, G; Zhao, S, 2005) |
| "Capecitabine (350 mg/kg) was administered on days 0 to 13 and 24 to 37." | 1.33 | Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. ( Blanquicett, C; Buchsbaum, DJ; Carpenter, MD; Chhieng, DC; Diasio, RB; Eloubeidi, M; Johnson, MR; Russo, S; Saif, MW; Sellers, JC; Vickers, SM, 2005) |
| "Pancreatic neoplasms are associated with a poor prognosis, regardless of treatment modality." | 1.33 | Resection and use of a cyclooxygenase-2 inhibitor for treatment of pancreatic adenocarcinoma in a cockatiel. ( Bartick, T; Chen, S, 2006) |
| " Recent studies had shown that the long-term use of high concentration of COX-2 inhibitors is not toxic free and may be limited due to serious gastrointestinal and cardiovascular side effects." | 1.33 | Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. ( Arber, N; Ben-Yosef, R; Figer, A; Kazanov, D; Lev-Ari, S; Starr, A; Yona, D; Zinger, H, 2005) |
| "In the present study, we used a pancreatic cancer model to determine the role of Sp1 in the antitumor activity of celecoxib." | 1.32 | Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. ( Abbruzzese, JL; He, Y; Wang, L; Wei, D; Xie, K; Xiong, HQ, 2004) |
| "Advanced human pancreatic cancer is considered a chemoresistant disease." | 1.32 | [A case of advanced pancreatic cancer with remarkable response to thalidomide, celecoxib and gemcitabine]. ( Hada, M; Mizutari, K, 2004) |
| "The prognosis of pancreatic cancer with metastases or recurrence is quite poor." | 1.32 | [A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan]. ( Hada, M; Mizutari, K, 2004) |
| "After establishment of pancreatic cancer, groups 1 and 5 received no therapy, groups 2 and 6 were fed 7 mg Celebrex daily, groups 3 and 7 were given 28 mg Zyflo and groups 4 and 8 received Celebrex and Zyflo orally daily in weeks 17-32." | 1.31 | Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters. ( Achucarro, P; Guski, H; Heinicken, D; Jacobi, CA; Kilian, M; Müller, JM; Schimke, I; Wenger, FA, 2002) |
| "However, it is still unknown whether pancreatic cancer might also be influenced." | 1.31 | Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters. ( Bisevac, M; Guski, H; Khodadayan, C; Kilian, M; Müller, JM; Schimke, I; von Seebach, M; Wenger, FA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 37 (64.91) | 29.6817 |
| 2010's | 18 (31.58) | 24.3611 |
| 2020's | 2 (3.51) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Q | 1 |
| Wang, J | 1 |
| Zhang, Q | 1 |
| Zhang, J | 2 |
| Lou, Y | 1 |
| Yang, J | 1 |
| Chen, Y | 1 |
| Wei, T | 1 |
| Fu, Q | 1 |
| Ye, M | 1 |
| Zhang, X | 2 |
| Dang, X | 1 |
| Liang, T | 1 |
| Bai, X | 1 |
| Li, D | 1 |
| Ma, Y | 1 |
| Liu, W | 1 |
| Ren, X | 2 |
| Chen, M | 1 |
| Xu, X | 1 |
| Sheng, Z | 1 |
| Zhang, K | 2 |
| Zhou, R | 1 |
| Goodin, S | 2 |
| Zheng, X | 3 |
| Xu, XT | 1 |
| Chen, J | 1 |
| Ma, YR | 1 |
| Wang, X | 2 |
| Ma, YY | 1 |
| Zhao, DG | 1 |
| Zhou, RP | 1 |
| Li, DL | 1 |
| Solheim, TS | 1 |
| Laird, BJA | 1 |
| Balstad, TR | 1 |
| Stene, GB | 1 |
| Bye, A | 1 |
| Johns, N | 1 |
| Pettersen, CH | 1 |
| Fallon, M | 1 |
| Fayers, P | 1 |
| Fearon, K | 1 |
| Kaasa, S | 1 |
| Zuo, C | 1 |
| Hong, Y | 1 |
| Qiu, X | 1 |
| Yang, D | 1 |
| Liu, N | 1 |
| Sheng, X | 1 |
| Zhou, K | 1 |
| Tang, B | 1 |
| Xiong, S | 1 |
| Ma, M | 1 |
| Liu, Z | 1 |
| Ding, N | 1 |
| Cui, XX | 1 |
| Gao, Z | 1 |
| Huang, H | 1 |
| Wei, X | 1 |
| Du, Z | 1 |
| Lin, Y | 1 |
| Shih, WJ | 1 |
| Rabson, AB | 1 |
| Conney, AH | 1 |
| Hu, C | 1 |
| Cheng, G | 1 |
| Zielonka, J | 1 |
| McAllister, D | 1 |
| Tsai, S | 1 |
| Dwinell, MB | 1 |
| Kalyanaraman, B | 1 |
| Li, S | 1 |
| Gu, Z | 1 |
| Xiao, Z | 1 |
| Zhou, T | 1 |
| Li, J | 2 |
| Sun, K | 1 |
| Luo, M | 1 |
| Wang, Y | 2 |
| Shang, B | 1 |
| Dong, L | 1 |
| Ali, S | 4 |
| Banerjee, S | 1 |
| Ahmad, A | 1 |
| El-Rayes, BF | 4 |
| Philip, PA | 4 |
| Sarkar, FH | 3 |
| Xu, XF | 1 |
| Xie, CG | 2 |
| Wang, XP | 3 |
| Liu, J | 1 |
| Yu, YC | 1 |
| Hu, HL | 1 |
| Guo, CY | 1 |
| Colby, JK | 1 |
| Klein, RD | 1 |
| McArthur, MJ | 1 |
| Conti, CJ | 1 |
| Kiguchi, K | 1 |
| Kawamoto, T | 1 |
| Riggs, PK | 1 |
| Pavone, AI | 1 |
| Sawicki, J | 1 |
| Fischer, SM | 1 |
| Yip-Schneider, MT | 1 |
| Wu, H | 2 |
| Njoku, V | 1 |
| Ralstin, M | 1 |
| Holcomb, B | 1 |
| Crooks, PA | 1 |
| Neelakantan, S | 1 |
| Sweeney, CJ | 1 |
| Schmidt, CM | 1 |
| Bergmann, F | 1 |
| Breinig, M | 1 |
| Höpfner, M | 1 |
| Rieker, RJ | 1 |
| Fischer, L | 1 |
| Köhler, C | 1 |
| Esposito, I | 1 |
| Kleeff, J | 1 |
| Herpel, E | 1 |
| Ehemann, V | 1 |
| Friess, H | 1 |
| Schirmacher, P | 1 |
| Kern, MA | 1 |
| Mukherjee, P | 1 |
| Basu, GD | 1 |
| Tinder, TL | 1 |
| Subramani, DB | 1 |
| Bradley, JM | 1 |
| Arefayene, M | 1 |
| Skaar, T | 1 |
| De Petris, G | 1 |
| Pino, MS | 1 |
| Milella, M | 2 |
| Gelibter, A | 2 |
| Sperduti, I | 1 |
| De Marco, S | 1 |
| Nuzzo, C | 1 |
| Bria, E | 2 |
| Carpanese, L | 1 |
| Ruggeri, EM | 2 |
| Carlini, P | 2 |
| Cognetti, F | 2 |
| Toomey, DP | 1 |
| Manahan, E | 1 |
| McKeown, C | 1 |
| Rogers, A | 1 |
| McMillan, H | 1 |
| Geary, M | 1 |
| Conlon, KC | 1 |
| Murphy, JF | 1 |
| Lipton, A | 2 |
| Campbell-Baird, C | 1 |
| Witters, L | 2 |
| Harvey, H | 2 |
| Stan, SD | 1 |
| Singh, SV | 1 |
| Brand, RE | 1 |
| Padillo, FJ | 2 |
| Ruiz-Rabelo, JF | 1 |
| Cruz, A | 2 |
| Perea, MD | 2 |
| Tasset, I | 1 |
| Montilla, P | 1 |
| Túnez, I | 2 |
| Muntané, J | 2 |
| Arjona-Sánchez, A | 1 |
| Ruiz-Rabelo, J | 1 |
| Vázquez, R | 1 |
| Muñoz, Mdel C | 1 |
| Morak, MJ | 1 |
| Richel, DJ | 1 |
| van Eijck, CH | 1 |
| Nuyttens, JJ | 1 |
| van der Gaast, A | 1 |
| Vervenne, WL | 1 |
| Padmos, EE | 1 |
| Schaake, EE | 1 |
| Busch, OR | 1 |
| van Tienhoven, G | 1 |
| Ding, X | 1 |
| Zhu, C | 1 |
| Qiang, H | 1 |
| Zhou, X | 1 |
| Zhou, G | 1 |
| Härdtner, C | 1 |
| Multhoff, G | 1 |
| Falk, W | 1 |
| Radons, J | 1 |
| Hill, R | 1 |
| Li, Y | 1 |
| Tran, LM | 1 |
| Dry, S | 1 |
| Calvopina, JH | 1 |
| Garcia, A | 1 |
| Kim, C | 1 |
| Donahue, TR | 1 |
| Herschman, HR | 1 |
| Lasalvia-Prisco, E | 1 |
| Goldschmidt, P | 1 |
| Galmarini, F | 1 |
| Cucchi, S | 1 |
| Vázquez, J | 1 |
| Aghazarian, M | 1 |
| Lasalvia-Galante, E | 1 |
| Golomar, W | 1 |
| Gordon, W | 1 |
| Al-Wadei, HA | 1 |
| Al-Wadei, MH | 1 |
| Ullah, MF | 1 |
| Schuller, HM | 1 |
| Wenger, FA | 3 |
| Kilian, M | 3 |
| Achucarro, P | 1 |
| Heinicken, D | 1 |
| Schimke, I | 3 |
| Guski, H | 2 |
| Jacobi, CA | 2 |
| Müller, JM | 2 |
| Levitt, RJ | 1 |
| Pollak, M | 1 |
| Bisevac, M | 1 |
| Khodadayan, C | 1 |
| von Seebach, M | 1 |
| Crane, CH | 1 |
| Mason, K | 1 |
| Janjan, NA | 1 |
| Milas, L | 1 |
| Rich, TA | 1 |
| Shepard, R | 1 |
| Dong, YW | 1 |
| Cai, JT | 1 |
| Qian, KD | 1 |
| Fife, RS | 1 |
| Stott, B | 1 |
| Carr, RE | 1 |
| Wei, D | 1 |
| Wang, L | 1 |
| He, Y | 1 |
| Xiong, HQ | 2 |
| Abbruzzese, JL | 2 |
| Xie, K | 1 |
| Di Cosimo, S | 1 |
| Malaguti, P | 1 |
| Pellicciotta, M | 1 |
| Terzoli, E | 1 |
| Hada, M | 2 |
| Mizutari, K | 2 |
| Raut, CP | 1 |
| Nawrocki, S | 1 |
| Lashinger, LM | 1 |
| Davis, DW | 1 |
| Khanbolooki, S | 1 |
| Xiong, H | 1 |
| Ellis, LM | 1 |
| McConkey, DJ | 1 |
| Kerr, S | 1 |
| Legore, K | 1 |
| Campbell, C | 1 |
| Plunkett, W | 1 |
| Wolff, R | 1 |
| Du, M | 1 |
| Lenzi, R | 1 |
| Graepler, F | 1 |
| Gregor, M | 1 |
| Lauer, UM | 1 |
| Wu, G | 1 |
| Yi, J | 1 |
| Di, F | 1 |
| Zou, S | 1 |
| Li, X | 1 |
| Gregor, JI | 1 |
| Heukamp, I | 1 |
| Kiewert, C | 1 |
| Kristiansen, G | 1 |
| Walz, MK | 1 |
| Zalupski, MM | 1 |
| Shields, AF | 1 |
| Ferris, AM | 1 |
| Vaishampayan, U | 1 |
| Heilbrun, LK | 1 |
| Venkatramanamoorthy, R | 1 |
| Adsay, V | 1 |
| Xu, G | 1 |
| Wu, K | 1 |
| Zhao, S | 1 |
| Ferrari, V | 1 |
| Valcamonico, F | 1 |
| Amoroso, V | 1 |
| Simoncini, E | 1 |
| Vassalli, L | 1 |
| Marpicati, P | 1 |
| Rangoni, G | 1 |
| Grisanti, S | 1 |
| Tiberio, GA | 1 |
| Nodari, F | 1 |
| Strina, C | 1 |
| Marini, G | 1 |
| Blanquicett, C | 1 |
| Saif, MW | 1 |
| Buchsbaum, DJ | 1 |
| Eloubeidi, M | 1 |
| Vickers, SM | 1 |
| Chhieng, DC | 1 |
| Carpenter, MD | 1 |
| Sellers, JC | 1 |
| Russo, S | 1 |
| Diasio, RB | 1 |
| Johnson, MR | 1 |
| Chen, S | 1 |
| Bartick, T | 1 |
| Lev-Ari, S | 2 |
| Zinger, H | 1 |
| Kazanov, D | 1 |
| Yona, D | 1 |
| Ben-Yosef, R | 1 |
| Starr, A | 1 |
| Figer, A | 1 |
| Arber, N | 2 |
| Jimeno, A | 1 |
| Amador, ML | 1 |
| Kulesza, P | 1 |
| Rubio-Viqueira, B | 1 |
| Chan, A | 1 |
| Wheelhouse, J | 1 |
| Kuramochi, H | 1 |
| Tanaka, K | 1 |
| Danenberg, K | 1 |
| Messersmith, WA | 1 |
| Almuete, V | 1 |
| Hruban, RH | 1 |
| Maitra, A | 1 |
| Yeo, CJ | 1 |
| Hidalgo, M | 1 |
| Cascinu, S | 1 |
| Scartozzi, M | 1 |
| Carbonari, G | 1 |
| Pierantoni, C | 1 |
| Verdecchia, L | 1 |
| Mariani, C | 1 |
| Squadroni, M | 1 |
| Antognoli, S | 1 |
| Silva, RR | 1 |
| Giampieri, R | 1 |
| Berardi, R | 1 |
| Wang, HY | 1 |
| Yang, YM | 1 |
| Zhuang, Y | 1 |
| Chen, HN | 1 |
| Wan, YL | 1 |
| Huang, YT | 1 |
| Lichtenberg, D | 1 |
| Dragovich, T | 1 |
| Burris, H | 1 |
| Loehrer, P | 1 |
| Von Hoff, DD | 1 |
| Chow, S | 1 |
| Stratton, S | 1 |
| Green, S | 1 |
| Obregon, Y | 1 |
| Alvarez, I | 1 |
| Gordon, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study[NCT01419145] | 46 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| 09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy[NCT02159248] | Phase 1 | 0 participants (Actual) | Interventional | 2014-03-31 | Withdrawn (stopped due to The study closed prior to enrolling any participants.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for celecoxib and Cancer of Pancreas
| Article | Year |
|---|---|
Chemoprevention strategies for pancreatic cancer.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2010 |
Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protoc | 2003 |
COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2003 |
[Anti-angiogenic therapy for gastrointestinal tumours].
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2005 |
Compositions for treatment of cancer and inflammation.
Topics: Apoptosis; Celecoxib; Cell Proliferation; Colorectal Neoplasms; Curcumin; Cyclooxygenase 2 Inhibitor | 2008 |
13 trials available for celecoxib and Cancer of Pancreas
| Article | Year |
|---|---|
A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer.
Topics: Aged; Cachexia; Celecoxib; Combined Modality Therapy; Dietary Supplements; Disease Management; Exerc | 2017 |
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2009 |
Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2010 |
Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Combined Modality Therapy; F | 2011 |
Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies.
Topics: Acetylcysteine; Angiogenesis Inhibitors; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma; Carci | 2012 |
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 2004 |
Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2004 |
A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administ | 2005 |
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2006 |
Assessment of celecoxib pharmacodynamics in pancreatic cancer.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Fem | 2006 |
COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug-Relat | 2008 |
39 other studies available for celecoxib and Cancer of Pancreas
| Article | Year |
|---|---|
Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Celecoxib; Ce | 2019 |
Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Celecoxib; Cell Line, Tumor; C | 2020 |
Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor | 2021 |
Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3 / NF-kB and L1CAM activities.
Topics: CD56 Antigen; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Down-Reg | 2018 |
A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvasta | 2014 |
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Proce | 2014 |
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Proce | 2014 |
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Proce | 2014 |
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Proce | 2014 |
Anti-tumor effect and mechanism of cyclooxygenase-2 inhibitor through matrix metalloproteinase 14 pathway in PANC-1 cells.
Topics: Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclooxygenas | 2015 |
Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells.
Topics: Adenocarcinoma; Apoptosis; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Line, Tumor; Cell Prolifera | 2016 |
Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2008 |
Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo.
Topics: Administration, Oral; Aged; Animals; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase | 2008 |
Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Transformation, Neoplastic | 2008 |
Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Proliferation; Chemokines, | 2008 |
Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Blotting, Western; Carcinoid Tumor; | 2009 |
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.
Topics: Adenocarcinoma; Animals; Antibodies; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Celecoxib; Cyclo | 2009 |
Vascular endothelial growth factor and not cyclooxygenase 2 promotes endothelial cell viability in the pancreatic tumor microenvironment.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Survival; Cyclooxy | 2010 |
Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer.
Topics: Animals; Antioxidants; Catalase; Celecoxib; Cricetinae; Cyclooxygenase 2 Inhibitors; Glutathione; Gl | 2010 |
Effects of capecitabine and celecoxib in experimental pancreatic cancer.
Topics: Animals; Capecitabine; Celecoxib; Cricetinae; Deoxycytidine; Fluorouracil; Lipid Peroxidation; Lipid | 2010 |
Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors.
Topics: Adenocarcinoma; Arachidonate 5-Lipoxygenase; Celecoxib; Cell Division; Cell Line, Tumor; Cyclooxygen | 2011 |
(-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Camellia sinensis; Caspases; Catechin; Celecoxib; Cell Line | 2012 |
Cell intrinsic role of COX-2 in pancreatic cancer development.
Topics: Animals; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Membrane; Cyclooxygenase 2; Disease Models, A | 2012 |
Celecoxib and GABA cooperatively prevent the progression of pancreatic cancer in vitro and in xenograft models of stress-free and stress-exposed mice.
Topics: Animals; Arachidonate 5-Lipoxygenase; Celecoxib; Cell Movement; Cell Proliferation; Cyclic AMP; Cycl | 2012 |
Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Celecoxib; Cricetinae; Glutathione; Hydroxyurea; Inc | 2002 |
Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibito | 2002 |
Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cricetinae; Hydroxyurea; Lipid Peroxida | 2002 |
[Effect of selective cyclooxygenase-2 inhibitor celebrex on expression of vascular endothelial growth factor (VEGF) in pancreatic carcinoma].
Topics: Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Humans; | 2003 |
Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro.
Topics: Apoptosis; Breast Neoplasms; Caspases; Celecoxib; Cell Division; Cyclooxygenase Inhibitors; DNA; End | 2004 |
Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity.
Topics: Adenocarcinoma; Animals; Celecoxib; Cyclooxygenase Inhibitors; Electrophoretic Mobility Shift Assay; | 2004 |
[A case of advanced pancreatic cancer with remarkable response to thalidomide, celecoxib and gemcitabine].
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
[A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase 2; Dru | 2004 |
Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Celecoxib; Cyclooxygena | 2004 |
Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.
Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Deoxycytidine; Gemcitabine; | 2004 |
Celecoxib inhibits proliferation and induces apoptosis via cyclooxygenase-2 pathway in human pancreatic carcinoma cells.
Topics: Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; | 2005 |
Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster.
Topics: Animals; Carcinoma, Pancreatic Ductal; Celecoxib; Cricetinae; Cyclooxygenase Inhibitors; Dinoproston | 2005 |
[Enhancing effects of celecoxib on the growth inhibition of pancreatic carcinoma by gemcitabine treatment].
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Celecoxib; Cell Cycle; Cyclooxygenase Inhibitor | 2005 |
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Topics: 5'-Nucleotidase; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2005 |
Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.
Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Electrophoretic Mobility Shift Assay; ErbB | 2005 |
Resection and use of a cyclooxygenase-2 inhibitor for treatment of pancreatic adenocarcinoma in a cockatiel.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Bird Diseases; Celecoxib; Cockatoos; Cyclooxygenas | 2006 |
Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Celecoxib; Cell Line, Tumor; Ce | 2005 |
The effect of celecoxib on tissue factor expression in pancreatic cancer cells.
Topics: Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Gene Expression Regulation; Humans; NF-kap | 2007 |